David A. Knorr

4.4k total citations
54 papers, 2.9k citations indexed

About

David A. Knorr is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, David A. Knorr has authored 54 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 24 papers in Immunology and 22 papers in Molecular Biology. Recurrent topics in David A. Knorr's work include CAR-T cell therapy research (16 papers), Immune Cell Function and Interaction (14 papers) and Monoclonal and Polyclonal Antibodies Research (12 papers). David A. Knorr is often cited by papers focused on CAR-T cell therapy research (16 papers), Immune Cell Function and Interaction (14 papers) and Monoclonal and Polyclonal Antibodies Research (12 papers). David A. Knorr collaborates with scholars based in United States, France and Australia. David A. Knorr's co-authors include Dan S. Kaufman, Vitaly Citovsky, William O. Dawson, Patricia Zambryski, Gadi Schuster, Zhenya Ni, Michael R. Verneris, Laura E. Bendzick, Patrick Q. Hearne and T.J. Morris and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

David A. Knorr

51 papers receiving 2.8k citations

Peers

David A. Knorr
Isao Ishida Japan
Geert Plaetinck Switzerland
Thomas J. Cradick United States
Luhan Yang United States
Seung Woo Cho South Korea
Peter D. Rathjen Australia
Meagan E. Sullender United States
Joshua A. Weinstein United States
Masaaki Oyama Japan
Éric Batsché France
Isao Ishida Japan
David A. Knorr
Citations per year, relative to David A. Knorr David A. Knorr (= 1×) peers Isao Ishida

Countries citing papers authored by David A. Knorr

Since Specialization
Citations

This map shows the geographic impact of David A. Knorr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Knorr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Knorr more than expected).

Fields of papers citing papers by David A. Knorr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Knorr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Knorr. The network helps show where David A. Knorr may publish in the future.

Co-authorship network of co-authors of David A. Knorr

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Knorr. A scholar is included among the top collaborators of David A. Knorr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Knorr. David A. Knorr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Osorio, Juan C., David A. Knorr, Polina Weitzenfeld, et al.. (2025). Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. Cancer Cell. 43(10). 1902–1916.e9. 2 indexed citations
3.
Bouberhan, Sara, Konstantinos Papadimitriou, Rebecca C. Arend, et al.. (2024). A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS5632–TPS5632. 7 indexed citations
4.
5.
Knorr, David A., Lucas Blanchard, Rom S. Leidner, et al.. (2023). FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. Cancer Immunology Research. 12(3). 322–333. 18 indexed citations
6.
Knorr, David A., et al.. (2022). Central Diabetes Insipidus Induced by Acute Myeloid Leukemia with DNMT3A Mutation. SHILAP Revista de lepidopterología. 2022. 1–3.
7.
Tamari, Roni, Ioannis Politikos, David A. Knorr, et al.. (2021). Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy. Blood Cancer Discovery. 2(6). 577–585. 41 indexed citations
8.
Li, Chao, Gene Chong, Guanghui Zong, et al.. (2021). Site-Selective Chemoenzymatic Modification on the Core Fucose of an Antibody Enhances Its Fcγ Receptor Affinity and ADCC Activity. Journal of the American Chemical Society. 143(20). 7828–7838. 20 indexed citations
9.
Roeker, Lindsey E., David A. Knorr, Melissa S. Pessin, et al.. (2020). Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia. 34(11). 3047–3049. 63 indexed citations
10.
Quesada, Andres, et al.. (2020). Spontaneous Remission in a Patient With Acute Myeloid Leukemia Leading to Undetectable Minimal Residual Disease. Journal of Hematology. 9(1-2). 18–22. 9 indexed citations
11.
Knorr, David A., Hongbo Wang, Margaret L. MacMillan, et al.. (2016). Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation. 22(5). 825–833. 12 indexed citations
12.
Knorr, David A., Veronika Bachanová, Michael R. Verneris, & Jeffrey S. Miller. (2014). Clinical utility of natural killer cells in cancer therapy and transplantation. Seminars in Immunology. 26(2). 161–172. 136 indexed citations
13.
Knorr, David A., Allison M. Bock, Renier J. Brentjens, & Dan S. Kaufman. (2013). Engineered Human Embryonic Stem Cell-Derived Lymphocytes to Study In Vivo Trafficking and Immunotherapy. Stem Cells and Development. 22(13). 1861–1869. 21 indexed citations
14.
Geller, Melissa A., David A. Knorr, Laura E. Bendzick, et al.. (2013). Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model. Cytotherapy. 15(10). 1297–1306. 58 indexed citations
15.
Ni, Zhenya, David A. Knorr, & Dan S. Kaufman. (2013). Hematopoietic and Nature Killer Cell Development from Human Pluripotent Stem Cells. Methods in molecular biology. 1029. 33–41. 30 indexed citations
16.
Bock, Allison M., David A. Knorr, & Dan S. Kaufman. (2013). Development, Expansion, and <em>In vivo</em> Monitoring of Human NK Cells from Human Embryonic Stem Cells (hESCs) and Induced Pluripotent Stem Cells (iPSCs). Journal of Visualized Experiments. e50337–e50337. 36 indexed citations
17.
Tang, Ning, et al.. (2012). Antibody Purification with AssayMAP, a High Throughput Microchromatography Platform. Journal of Biomolecular Techniques JBT. 23. 1 indexed citations
18.
Knorr, David A., et al.. (1991). De novo generation of defective interfering RNAs of tomato bushy stunt virus by high multiplicity passage. Virology. 181(1). 193–202. 62 indexed citations
19.
Hearne, Patrick Q., David A. Knorr, Bradley I. Hillman, & T.J. Morris. (1990). The complete genome structure and synthesis of infectious RNA from clones of tomato bushy stunt virus. Virology. 177(1). 141–151. 179 indexed citations
20.
Citovsky, Vitaly, David A. Knorr, Gadi Schuster, & Patricia Zambryski. (1990). The P30 movement protein of tobacco mosaic virus is a single-strand nucleic acid binding protein. Cell. 60(4). 637–647. 376 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Isao Ishida Breakdown of academic impact, for papers by Geert Plaetinck Breakdown of academic impact, for papers by Thomas J. Cradick Breakdown of academic impact, for papers by Luhan Yang Breakdown of academic impact, for papers by Seung Woo Cho Breakdown of academic impact, for papers by Peter D. Rathjen Breakdown of academic impact, for papers by Meagan E. Sullender Breakdown of academic impact, for papers by Joshua A. Weinstein Breakdown of academic impact, for papers by Masaaki Oyama Breakdown of academic impact, for papers by Éric Batsché
Rankless by CCL
2026